Section
Bispecific anti-BCMA/GPRC5D CAR T cells demonstrate high response rates and manageable safety in patients with relapsed/refractory multiple myeloma complicated by extraosseous extramedullary disease, a group with historically poor outcomes.
This study assesses the predictive accuracy of the MSKCC CT-based model for residual disease after neoadjuvant chemotherapy in advanced ovarian cancer, showing limited discrimination that improves with optimized clinical parameters. CT find
This study quantifies health-related quality of life impacts associated with risk-reducing hysterectomy, with and without bilateral salpingo-oophorectomy, to aid counseling and economic evaluation in endometrial cancer prevention.
The CLAEG study prospectively evaluated radical surgery in adenocarcinoma of the oesophagogastric junction, demonstrating that prioritizing abdominal lymphadenectomy, neoadjuvant therapy, total gastrectomy, and laparoscopic approaches yield
This randomized trial analysis compares the costs and quality-adjusted life years of robotic versus open pancreatoduodenectomy, revealing no significant cost differences but a lower probability that robotic surgery is cost-effective at six
The SENTIX study demonstrates that sentinel lymph node biopsy preserves quality of life, reduces lymphoedema incidence, and lowers early postoperative complications compared to pelvic lymphadenectomy in early-stage cervical cancer patients.
A retrospective study delineates relapse risks and survival outcomes in adult acute myeloid leukemia patients who achieve first complete remission without undergoing allogeneic stem cell transplantation, highlighting venetoclax’s role in re
This study compares outcomes of CAR T-cell therapy and allogeneic stem cell transplantation based on IPI risk factors in relapsed/refractory LBCL, highlighting favorable survival with CAR T-cell therapy in low-risk patients but advocating a
A quality improvement project demonstrates the feasibility and high patient satisfaction of a smartphone app for daily symptom tracking and timely intervention after pancreatic surgery, potentially reducing complications and readmissions.
A novel chemotherapy-free regimen combining mosunetuzumab with response-adapted polatuzumab vedotin and obinutuzumab shows high complete response rates and durable progression-free survival in untreated indolent B-cell NHL with favorable sa
Pediatric and young adult survivors of differentiated thyroid cancer face a significant long-term risk of second primary malignancies, especially with radioactive iodine treatment, highlighting the need for extended surveillance and tailore
Emerging evidence suggests menopausal estrogen-only therapy post-hysterectomy may reduce breast cancer risk both in general and BRCA mutation populations. Shared decision-making is key when considering therapy and surgical options for benig
A recent study comparing tissue-free and tumor-informed ctDNA assays in early triple negative breast cancer reveals comparable accuracy and earlier detection of molecular residual disease, supporting tissue-free approaches for routine clini
Since 2012, waiting times from diagnosis to first cancer surgery have significantly increased across major US cancers, disproportionately affecting vulnerable populations and high-volume academic centers, underscoring urgent need for system
Persistent low-level hCG following gestational trophoblastic disease often resolves spontaneously. Key clinical and biochemical predictors can identify patients at higher risk for subsequent neoplasia, guiding optimal surveillance.
A large Latin American study shows radiofrequency ablation is a safe, effective minimally invasive alternative for T1a low-risk papillary thyroid cancer, with excellent tumor disappearance rates and minimal complications over 18 months foll
This study reveals a significant early onset of metabolic syndrome in men with prostate cancer treated with combined ADT and ARPI therapies, highlighting the necessity for multidisciplinary metabolic monitoring and interventions.
A clear, practice-focused summary of the 2026 ASCO living guideline on systemic treatment of metastatic castration‑resistant prostate cancer, emphasizing biomarker-driven choices, sequencing, and new options such as 177Lu‑PSMA and PARP inhi
This phase II trial demonstrates significant antitumor activity of trastuzumab rezetecan in both HER2-high and HER2-low advanced salivary gland carcinoma with a manageable safety profile, offering new hope for this challenging malignancy.
HER2 expression in recurrent cervical cancer varies notably by histology and recurrence site, underscoring the importance of reassessment to guide HER2-targeted treatments effectively.
